Inhibikase Therapeutics (IKT) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SAB Biotherapeutics (SABS) has outperformed Inhibikase Therapeutics (IKT) over the past year, gaining 23.1% versus a gain of 19.8%. Over five years, IKT leads with a -83.2% price change compared with -97.1% for SABS. Inhibikase Therapeutics is the larger company by market cap ($266.5 million vs $263.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IKT | SABS |
|---|---|---|
| Share price | $1.91 | $2.89 |
| Market cap | $266.51M | $262.95M |
| 1-day change | -1.55% | +0.35% |
| YTD return | -5.37% | -22.99% |
| 1-year return | +19.75% | +23.08% |
| 5-year return | -83.25% | -97.15% |
| EPS (TTM) | $-0.43 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.61 | $5.15 |
| 52-week low | $1.33 | $2.10 |
| Distance from 52-week high | -26.82% | -43.88% |
| Analyst consensus | none | none |
| Avg. price target upside | +214.14% | +302.77% |
| Average volume | 656.02K | 489.83K |
| Shares outstanding | 139.54M | 90.99M |
| Employees | 35 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees
IKT vs SABS FAQ
Which is bigger, Inhibikase Therapeutics or SAB Biotherapeutics?
Inhibikase Therapeutics (IKT) is larger, with a market capitalization of $266.51M compared with $262.95M for SAB Biotherapeutics (SABS).
Which stock has performed better over the past year, IKT or SABS?
SABS returned +23.08% over the past 12 months, compared with +19.75% for IKT (price return, excluding dividends). Past performance does not predict future results.
Are Inhibikase Therapeutics and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.